<DOC>
	<DOCNO>NCT00766896</DOCNO>
	<brief_summary>STUDY QUESTIONS - What real prevalence platelet `` resistance '' aspirin acute phase stroke 3 month , 1 year , measure use different platelet function test ? - Do method measure similar level resistance , method sensitive others ? - Does resistance result bad clinical prognosis ? Is result independent variable ? OBJECTIVES 1 . Hospital Phase ( Acute Stroke ) - Determination , use various method , prevalence platelet hyperreactivity patient treat aspirin treat ischemic stroke ( acute phase ) - Comparison different assessment method identification accurate - Identification variable correlate platelet hyperreactivity 2 . Follow-up Phase - Correlation platelet hyperreactivity important clinical outcome 12 , 24 , 36 month - Correlation platelet hyperreactivity death dependency hospital discharge , 3 , 12 , 24 , 36 month ( Modified Rankin Scale ) - Correlation platelet hyperreactivity recurrent stroke type - Correlation different method evaluate platelet function identification accurate method - Analysis hyperreactivity time THE STUDY - The study include 200 consecutive patient see emergency department large , urban hospital ( 1500 inpatient bed ) diagnose stroke acute phase ; patient treat aspirin undetermined period - The investigator include patient require full anticoagulation treatment , regardless cause - Importantly , analysis primary secondary outcome carry blind examiner result platelet aggregation test PLATELET TESTS - Whole Blood Aggregometer , ChronoLog - VerifyNow , Accumetrics - PFA-100 , Siemens - Plateletworks , Helena - Impact-R , Diamed - Serum thromboxane B2</brief_summary>
	<brief_title>Platelet Hyperreactivity Aspirin Stroke</brief_title>
	<detailed_description>THE CONTEXT Aspirin anti-thrombotic therapy choice patient acute chronic phase vascular , cardiac , neurological disease , unless specific indication sodium warfarin ( instance , cardiac thrombus , chronic atrial fibrillation , cardio-embolic ischemic stroke ) . Recent study , include meta-analyses , suggest 5-60 % patient cardiovascular disease use aspirin show platelet resistance drug . However , available study include several methodological error make interpretation practical application difficult . Thus , incidence outcome platelet resistance remain poorly understood , especially patient ischemic stroke . Moreover , study include patient ambulatory follow-up THERAPY WITH ASPIRIN The dose aspirin prescribe study 300 mg orally nasogastric tube day ( assist therapy ) , first dose tomography soon admission patient indication thrombolytic therapy . After acute phase , patient receive aspirin dose 200 mg/day . Aspirin administer `` simple '' preparation ( buffer , extend release ) ANALYSIS OF OUTCOME DURING THE HOSPITAL PHASE The outcome assess daily hospitalization patient discharge . The physician , patient , researcher access result test platelet function . The number day hospitalization review , include number day hospitalization intensive care unit . Deaths analyze , cause death describe detail case . Electrocardiograms examine experienced cardiologist . Echocardiograms examine experienced cardiologist specialize method . Tomography examine experienced neuroradiologist , resonance/resonance angiography evaluate another experienced neuroradiologist ; blind platelet result . Outcomes judge committee contain neurologist , hematologist , neuroradiologist , cardiologist , epidemiologist , blind result platelet function MONITORING AND MANAGEMENT AFTER HOSPITAL DISCHARGE Outcomes analyze interview 3 , 12 , 24 , 36 month initial neurological event , well monthly telephone interview . Potential adverse outcome ( death , hospitalization , diagnostic test conduct , request treatment condition , new onset symptom ) assess detail committee investigator study . During evaluation , doctor , patient , researcher access result test platelet function . The outcome judge committee comprise neurologist , hematologist , neuroradiologist , cardiologist , epidemiologist , blind platelet test result Adherence ( daily use ) investigate active manner return visit monthly telephone contact . This study include interview patient separate interview family , addition review package aspirin . In addition , adherence assess measure serum thromboxane B2 . - Monthly telephone contact patient family use determine whether patient remain stable adverse outcome ( die , need seek medical care , present new symptom ) . In presence outcome , investigate detail ( death certificate , report hospital stay , analysis diagnostic test perform ) . In addition , investigate record medical report associate inquiry admission . - The evaluation three twelve month consist variety test platelet function ; addition , standardized questionnaire administer . Patients attend consultation contact within 30 day . If patient still attend consultation ( e.g. , difficulty walk ) , researcher go patient 's home . SEVERE BLEEDING - Any fatal bleeding event ( cause describe ) - Life-threatening bleeding : drop hemoglobin least 50 g/L , hypotension require inotropes ( hemorrhagic shock ) ; symptomatic intracranial hemorrhage ; transfusion least 4 unit red blood cell - Major bleeding , define significantly disable ( persistent sequela ) ; intraocular bleeding lead significant loss vision ; transfusion 1-3 unit red blood cell DEFINITION OF HYPERREACTIVITY TO ASPIRIN - For PFA-100 use cartridge C-EPI ( collagen-epinephrine ) : occlusion time &lt; 150 second - Chrono-Log Model 700 Whole-Blood : 0 Ω 0.75 mM arachidonic acid - Chrono-Log Model 700 Whole-Blood : collagen 1 mg/L 5 mg/L , accord formula 1 - ( Rate aggregation 1 mg / Rate aggregation 5 mg ) . Hyperreactivity define value 0.50 - - Chrono-Log Model 700 Whole-Blood : collagen 1 mg/L 10 Ω - Plateletworks : aggregation 60 % arachidonic acid consider resistant - VerifyNow Aspirin Assay ( Accumetrics ) : ≥ 550 aspirin reaction unit ( ARUs ) - Impact-R ( Diamed ) &gt; 3.2 % platelet aggregate surface plate incubation arachidonic acid COLLECTION OF BLOOD Blood sample collect arrival ED ( first dose aspirin ) , fifth day hospitalization , three month , 12 month . Samples collect 9 12 AM fast overnight , except sample take arrival ED . The blood collect antecubital vein , another vein necessary , bottle citrate ( 3.2 % ; Vacuette , Greiner Bio-One ) directly Plateletworks bottle kit . Samples total approximately 20 ml . The tourniquet apply 30 second movement allow collection . In order prevent platelet activation induce collection , even precaution , first 5 ml sample discard . The bottle fill top gently invert five time obtain correct mixture blood anticoagulant . In Plateletworks test , assays conduct within 10 minute collection ; remain assay conduct within 30 minute AGGREGOMETRY BY MEASURING THE IMPEDANCE OF WHOLE BLOOD USING CHRONOLOG MODEL 700 AND SOFTWARE ( AGGRO/LINK-8 , PA , USA ) After collect citrated whole blood , sample process 30 minute . Whole blood dilute 1:1 sterile saline ( 0.9 % ) stimulate one several reagent ( Chrono-Log , 0.5 mM arachidonic acid , 1 g/L collagen , 5 g/L collagen ) . The maximum impedance measure use two electrode immerse sample 6 minute express Ω. PFA-100 ( PLATELET FUNCTION ANALYZE-100 , SIEMENS , USA ) Blood specimens PFA-100® assay test accord manufacturer 's instruction . For sample , PFA-100® self-test procedure run analysis . Testing perform use citrated whole blood collagen-epinephrine cartridge . Whole blood aspirate condition high shear stress 150-µm aperture cover membrane impregnate collagen epinephrine . The time take occlude aperture platelet plug record closure time ( measured second ) . DETERMINATION OF SERUM THROMBOXANE B2 - ELISA After collection , blood immediately centrifuge ( +4 °C ) , plasma immediately frozen liquid nitrogen ( -190 °C ) transfer -80 °C freezer . Serum thromboxane B2 measure ELISA duplicate accord manufacturer 's instruction , express ng/ml . PLATELETWORKS ( HELENA CORPORATION , USA ) Briefly , collection blood kit contain arachidonic acid , collagen , ADP EDTA , platelet count make impedance measurement ( Horiba ABX , Montpellier , France ) , accordance standard protocol Helena Laboratories ( Helena Point Care ® , Texas , USA ) . The percentage platelet aggregation calculate use follow formula : % aggregation = [ platelet EDTA - platelet agonist ] / platelet EDTA x 100 VERIFYNOW ASPIRIN , ACCUMETRICS , USA The VerifyNow Aspirin point-of-care system ( Accumetrics , San Diego , CA , USA ) base turbidimetric optical detection platelet aggregation whole blood . Whole blood transfer standard cartridge contain lyophilized preparation human fibrinogen-coated bead arachidonic acid . As aggregation occur , system convert luminosity transmittance result aspirin reaction unit ( ARUs ) . IMPACT-R , DIAMED , USA Citrated blood ( 130 μL ) place test kit ( well ) accord manufacturer 's protocol , subject shear flow use rotate cone 2 minute ( 1800 s-1 ) . The well wash stain May Grünwald . The adhesion platelet surface evaluate use image analysis system connect Impact-R , result express percentage stain area . STATISTICAL ANALYSIS For calculation , use software IBM SPSS 21.0 Windows ( SPSS Inc , Chicago , IL , USA ) . The database create SPSS Data Entry Builder 4.0 use double entry input system . TIMETABLE FOR IMPLEMENTATION OF THE PROJECT Phase No . Months Calendar Dates Trial Activities Estimates 1 . 13 03/2007 - 04/2008 Protocol Development 2 . 2 05/2008 - 06/2008 Procedure Finalization 3 . 5 07/2008 - 12/2008 Protocol Revision 4 . 6 01/2009- 06/2009 Training 5 . 12 07/2009 - 06/2010 Main trial recruitment emergency room 6 . 36 08/2009 - 06/2013 Follow-up 7 . 3 07/2013 - 10/2013 Analysis reporting . CONFLICT OF INTEREST There external influence sponsor survey , collection , analysis data . Similarly , statistical analysis , preparation publication manuscript conduct entirely researcher , work together epidemiologist statisticians Faculty Medicine , USP . Companies institution provide kit equipment platelet test describe presentation conference publication</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Consecutive patient diagnosis ischemic stroke acute phase treat aspirin indefinite period The need full anticoagulation therapy pulmonary embolism , deep vein thrombosis , chronic atrial fibrillation , thrombus leave atrium leave ventricle , reason deem relevant patient 's physician Thrombolytic treatment stroke History allergy aspirin ( hive , swell glottis anaphylaxis ) Risk excessive bleeding due active peptic ulcer , liver failure , history bleed bleed diathesis Scheduled major vascular surgery Metastatic cancer survival estimate less year Creatinine clearance 30 mL/min Platelet count &lt; 100,000/mm3 Hematocrit &lt; 30 % Lipaemic blood Difficult followup : patient serious social problem , alcoholic , resident state country Refusal participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Cerebral Infarction</keyword>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Platelet Activation</keyword>
	<keyword>Platelets</keyword>
	<keyword>Platelet Function Tests</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Ischemia</keyword>
	<keyword>Thrombosis</keyword>
</DOC>